Abbott ended the first quarter with earnings per share up to $0,41, above the analyst estimate (5 cents) and guidance range ($0,34-0,36). Diluted earnings per share from continuing operations were $0,22.
The pharmaceutical company confirms its full-year 2014 earnings per share target in the range of $2,16 to $2,26. Global revenue increased 0,5% on an operating basis (excluding exchange rate effect) to $5,24 billion for the quarter due to growth in the diagnostics and adult nutrition business, as well as in treatment of vision disorders (ophthalmological sector).
Sales in the first quarter are in line with the January forecast and sales growth is expected to accelerate throughout the year with new product launches.
